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Summary  
Involvement of the internal female reproductive organs by diffuse large B-cell lymphoma (DLBCL) is 
uncommon, and there are sparse data describing the outcomes of such cases. In total, 678 female 
patients with DLBCL staged with PET/CT and treated with rituximab-containing chemotherapy were 
identified from databases in Denmark, Great Britain, Australia, and Canada. Overall, 27/678 (4%) had 
internal reproductive organ involvement: uterus (n=14), ovaries (n=10), or both (n=3). In multivariate 
analysis, women with uterine DLBCL experienced inferior PFS and OS compared to those without 
reproductive organ involvement, whereas ovarian DLBCL was not predictive of outcome. Secondary 
CNS involvement (SCNS) occurred in 7/17 (41%) women with uterine DLBCL (two patients with 
concomitant ovarian DLBCL) and 0/10 women with ovarian DLBCL without concomitant uterine 
involvement. In multivariate analysis adjusted for other risk factors for SCNS, uterine involvement by 
DLBCL remained strongly associated with SCNS (HR 14.13, 95%CI 5.09-39.25, P<0.001). Because 
involvement of the uterus by DLBCL appears to be associated with a high risk of SCNS, those patients 
should be considered for CNS staging and prophylaxis. However, more studies are needed to 
determine whether the increased risk of secondary CNS involvement also applies to women with 
localized reproductive organ DLBCL. 
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Introduction  
Clinical prognostic scores such as the International Prognostic Index (IPI) and the revised IPI (R-IPI) are 
widely used to predict the outcome of patients with newly diagnosed diffuse large B-cell lymphoma 
(DLBCL).(1993, Sehn, et al 2007) Enhanced discrimination of low- and high-risk patients was reported 
with the recently developed National Comprehensive Cancer Network (NCCN) IPI (NCCN-IPI), which 
refined the categorization of age and LDH into more prognostic subgroups and defined bone marrow, 
central nervous system (CNS), liver/gastrointestinal tract, or lung involvement as poor-risk 
features.(Zhou, et al 2014) While these risk models predict outcome in the large majority of patients 
with DLBCL, they do not adequately describe the natural history of specific extranodal presentations 
of DLBCL. For example, testicular DLBCL has a relapse pattern that frequently involves the CNS and 
with relapse risk still being present several years after treatment.(Cheah, et al 2014, Fonseca, et al 
2000, Vitolo, et al 2011, Zucca, et al 2003) Awareness of increased risk of secondary CNS involvement 
(SCNS) in patients with testicular DLBCL has led to development of treatment protocols, which include 
CNS prophylaxis first line.(Tilly, et al 2015, Vitolo, et al 2011) Kidney/adrenal involvement by DLBCL 
confers similar predilection for SCNS and is one of the six individual risk factors in the recently 
published CNS-IPI model.(Savage, et al 2014, Villa, et al 2011)  
The outcome and relapse pattern of DLBCL involving the female reproductive organs (uterus and/or 
ovaries), however, have not been studied in details. In a recent Danish-Canadian study, DLBCL 
involving the female reproductive organs was associated with very poor outcomes, and a study of 323 
Chinese DLBCL patients suggests that an increased frequency of SCNS may partially account for this 
finding.(Cao, et al 2014, El-Galaly, et al 2015) To study this issue more systematically, we analyzed the 
clinical characteristics, outcomes, and relapse pattern of women with internal reproductive organ 
DLBCL in a large cohort of R-CHOP(-like) treated female patients staged with 18F-fluoro-deoxyglucose-
positron emission tomography/computed tomography (FDG PET/CT).  
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Methods 
Patients 
This is an international retrospective study of female patients with newly diagnosed DLBCL. Patients 
were identified from lymphoma registries and study databases in Denmark (LYFO), Australia (Peter 
MacCallum Cancer Centre, Melbourne), Great Britain (Guy’s and St. Thomas’ Hospital, London), and 
Canada (British Columbia Cancer Agency, Vancouver). The regional/national lymphoma registries have 
been described in detail elsewhere.(Gang, et al 2012, Sehn, et al 2005) 
Patients diagnosed between 2001 and 2013 were screened for eligibility, but the surveyed time for 
each hospital site depended on the local availability of PET/CT and database structure. Patients 
fulfilling the following criteria were included: i) treatment-naïve DLBCL without CNS and/or 
intraocular involvement, ii) PET/CT pre-treatment staging, and iii) R-CHOP(-like) front-line therapy. 
Baseline CNS staging with evaluation of cerebrospinal fluid and brain imaging were performed 
according to unit policy in place at the time and physician discretion. 
Baseline clinicopathologic characteristics and treatment information were retrieved from databases 
and registries. In case of missing information or if the databases/registries did not routinely capture 
key information, local investigators reviewed individual medical records. Medical records were 
reviewed for outcomes and in particular relapse site (SCNS) by local investigators. Female patients 
(n=192) from Aalborg (2007-2012), Rigshospitalet (2009-2012) and BCCA (2011-2012) were previously 
included in the analyses of PET/CT detected extranodal DLBCL and validation of clinical risk scores in a 
recent Danish-Canadian study.(El-Galaly, et al 2015) In that study, we found that female reproductive 
organ involvement was associated with inferior outcomes, but detailed analyses of sites (ovarian 
and/or uterine), relapse patterns, and outcomes were not presented.(El-Galaly, et al 2015) 
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Treatment 
All patients were treated with R-CHOP(-like) first-line therapies. The CHOP-like therapies included R-
CEOP (doxorubicin replaced by etoposide) for patients with cardiac contraindications for 
anthracycline therapy and R-CHOEP (addition of etoposide 100 mg/m2 for three days with each R-
CHOP cycle) for selected high-risk patients in Denmark.(Gang, et al 2012) 
There were no predetermined indications for CNS prophylaxis, although it was generally considered in 
patients with high-risk features such as multiple extranodal sites of involvement and involvement of 
particular extranodal sites such as kidneys/adrenals. The prophylactic strategy, including drug, dose, 
route, and frequency varied according to local guidelines. Similarly, there were no predetermined 
guidelines for monitoring development of SCNS in asymptomatic patients in follow-up after 
completion of primary therapy. However, as a rule, routine surveillance studies did not include brain 
imaging or other CNS directed investigations. 
Radiotherapy was used at the discretion of the attending physician. Some of the commonly accepted 
indications for radiotherapy included solitary extranodal sites, bulky disease, residual PET activity 
following immunochemotherapy and combinations with abbreviated immunochemotherapy 
treatment for patients with stage I-II DLBCL. Data collection was compliant with local/national 
regulations.   
 
Statistical analyses  
Patient demographics and clinical characteristics were summarized using descriptive statistics 
(percentage for categorical values and median for continuous values).  Overall survival (OS) was 
measured from diagnosis until death from any cause, or censoring. Progression-free survival (PFS) was 
measured from diagnosis until progression/relapse, death, or censoring. PFS and OS were estimated 
using the Kaplan-Meier method, and compared using the log-rank test.(Kaplan and Meier 1958) 
Cumulative incidence curves for SCNS were computed using the competing risk regression method 
proposed by Fine and Gray.(Fine and Gray 1999) Univariate and multivariate associations between 
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clinicopathologic features and outcomes were examined using Cox proportional hazards regression 
models.(Cox 1972) In the multivariate models for PFS and OS, uterine involvement, ovarian 
involvement, and the individual risk factors of the International Prognostic Index (IPI) were included 
to adjust for confounding regardless of statistical significance in univariate analyses. (1993) (El-Galaly, 
et al 2015) 
 
Results  
Patients 
A total of 678 female DLBCL patients were included in the present study (Denmark n=469; Great 
Britain n=74; Australia n=91; Canada n=44). The median age was 65 years (range 17-91). R-CHOP was 
first line treatment in 93% of the patients, R-CEOP in 1%, and R-CHOEP in 6%. Radiotherapy was given 
to 32% of the patients and 17% received CNS prophylaxis (3% systemic prophylaxis, 7% intrathecal 
prophylaxis and 6% both types). With a median follow-up of 44 months (reverse Kaplan-Meier 
method), the 4-year PFS and OS rates were 71% (95% CI 67-74%) and 77% (95%CI 73-80%), 
respectively.  
Reproductive organ involvement was registered in 27/678 female DLBCL patients (4%, 95%CI 3-6%), 
of whom 14 had uterine involvement by DLBCL, 10 had ovarian involvement by DLBCL, and three had 
involvement of both organs. Table 1 shows the clinicopathologic characteristics of female DLBCL 
patients without reproductive organ involvement versus patients with ovarian involvement by DLBCL 
or patients with uterine involvement by DLBCL (including the three patients with concomitant ovarian 
and uterine DLBCL). Overall, female DLBCL patients with reproductive organ involvement had higher 
number of extranodal disease sites and patients with uterine involvement were more likely to have 
high-risk R-IPI risk score (Table 1). Kidney/adrenal involvement was associated with ovarian 
involvement by DLBCL (P=0.006). The proportions of patients receiving CNS prophylaxis and 
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radiotherapy did not differ for patients with or without reproductive organ involvement, although 
there was a trend toward more use of systemic prophylaxis among patients with ovarian DLBCL. 
 
Outcomes of patients with or without reproductive organ involvement 
There was no difference in PFS (P=0.36) or OS (P=0.42) in women with reproductive organ 
involvement between the patients from Aalborg, Copenhagen, and BCCA previously reported and 
patients from additional centres/other time periods in the current study. Similarly there was no 
difference in PFS (P=0.89) or OS (p=0.89) in women without reproductive organ involvement, 
permitting data pooling for the present analysis. The outcomes of patients with ovarian versus uterine 
(+/- simultaneous ovarian DLBCL) versus no reproductive organ involvement are shown in Table 2 and 
corresponding survival curves are shown in Figure 1A and 1B. Patients with uterine involvement by 
DLBCL had worse 4-yr PFS and OS estimates than female patients without reproductive organ 
involvement and those with only ovarian involvement by DLBCL. Associations between reproductive 
organ site and outcomes were explored in univariate and multivariate Cox regression analyses (Table 
3). By univariate analyses, all individual IPI risk factors as well as uterine involvement by DLBCL were 
associated with inferior PFS and OS. By multivariate analyses, uterine involvement remained 
independently associated with inferior PFS (HR=2.28, 95%CI 1.23-4.22, P=0.009)) and OS (HR 2.34, 
95%CI 1.21-4.52, P=0.012)). Ovarian DLBCL was not associated with outcome in multivariate analyses. 
 
Secondary CNS involvement (SCNS) 
SCNS occurred in 27/678 (4%) women during follow-up. The median time to CNS relapse was 9 
months (interquartile range 6-19). Eleven of the 27 (41%) patients had documented systemic 
progression/relapse at the time of SCNS. SCNS was detected by imaging in 17 patients (biopsied in 
nine patients), by positive CSF analysis for lymphoma in five patients, and by both imaging and CSF 
analysis in four patients. One patient had intravitreal relapse documented by ophthalmologic 
8 
 
evaluation and visual disturbances that improved with SCNS treatment. SCNS was diagnosed in 7/27 
(26%) women with and 20/651 (3%) women without reproductive organ involvement. Notably, none 
of the 10 patients with ovarian DLBCL as the only reproductive organ site developed SCNS in contrast 
to 7/17 patients (41%) with uterine DLBCL (including 2 patients with concomitant ovarian and uterine 
DLBCL). The 4-year cumulative risk of SCNS was significantly higher for patients with uterine 
involvement by DLBCL as compared to patients without ( Table 2, Figure 1C). By univariate Cox 
analysis, uterine involvement by DLBCL +/- ovarian involvement was associated with increased risk of 
SCNS (HR 16.51 95% 6.97-39.12, P<0.001). By multivariate analysis including elevated LDH, 
kidney/adrenal involvement, >1 extranodal site, and stage III/IV disease, all of which are well 
established risk factors for SCNS (Boehme, et al 2009, van Besien, et al 1998, Villa, et al 2011, Villa, et 
al 2010), the presence of uterine DLBCL remained associated with increased risk of CNS relapse (HR 
14.13, 95%CI 5.09-39.25, P<0.001). Among patients with uterine involvement, 5/7 (71%) with SCNS 
had CNS-IPI score 4-6 (high-risk) at diagnosis as compared to 2/10 patients (20%) without SCNS 
(P=0.058). Among patients with uterine involvement by DLBCL, 0/7 with SCNS had stage I-II DLBCL as 
compared to 3/10 (30%) without SCNS (P=0.23). Kidney/adrenal involvement was registered in 
27/678 patients (4%), of whom three (11%) developed SCNS. None of the three patients with 
concomitant kidney/adrenal and ovarian involvement developed SCNS. 
As SCNS was seen with unexpectedly high frequency among patients with uterine involvement by 
DLBCL, pathology files were reviewed. In 11/17 patients (65%), including four with SCNS, uterine 
involvement by DLBCL was documented by biopsy (in one case of coinciding ovarian and uterine 
DLBCL, ovarian biopsy was obtained).  
 
Discussion 
The present study examined the outcomes of female DLBCL patients with reproductive organ 
involvement. Among the 678 patients analysed in this study, patients with uterine involvement by 
DLBCL had very poor outcomes, whereas patients with ovarian DLBCL had outcomes similar to other 
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women. The poor outcomes observed for patients with uterine involvement were at least partially 
explained by an unexpectedly high frequency of SCNS. 
Internal reproductive organ involvement was seen in 4% (95%CI 3-6) of female DLBCL patients in the 
present study, which is slightly higher than the 2% reported by Cao et al.(Cao, et al 2014) However, 
the latter study only included primary uterine DLBCL defined as those patients with stage IE-IIE 
disease, which likely explains the higher frequency of reproductive organ involvement in our study as 
89% patients with reproductive organ involvement also had advanced stage disease.(Cao, et al 2014) 
Similar to testicular DLBCL and kidney/adrenal involvement, DLBCLs originating from the reproductive 
organs in females are rare and underscores the importance of large databases to study clinical 
associations and natural history of these unusual DLBCL presentations.(Cheah, et al 2014, Villa, et al 
2011)   
The outcomes of women with reproductive organ involvement in the present study were significantly 
worse than for women without reproductive organ involvement. With multiple other high-risk 
features being present in these patients, the specific contribution of reproductive organ involvement 
to the poor outcomes is difficult to assess. However, presence of uterine DLBCL remained associated 
with poor PFS and OS independent of the IPI risk factors in multivariate analyses. Cao et al evaluated 
six patients with DLBCL originating primarily from the reproductive organs, including four with uterine 
involvement and two with ovarian involvement. Despite IPI ≤1 for all patients, the median PFS was 
only 27 months in that study.(Cao, et al 2014) Mandato et al conducted an extensive literature review 
of 144 patients with uterine involvement by DLBCL from cases/case series and derived a mean OS of 
46 months from these data.(Mandato, et al 2014) The more favourable outcomes of uterine 
involvement by DLBCL in that study may be explained by the fact that >80% of the patients had 
limited stage disease.(Mandato, et al 2014) Vang et al reported a series of 26 patients with uterine 
involvement by lymphoma, mostly DLBCL, and treated at the MD Anderson Cancer Centre in the 
period 1981-1998.(Vang, et al 2000) In that study, 10/26 patients had localized disease, 12/26 had 
advanced stage disease, and in 4/26 staging information was insufficient to determine disease stage. 
The outcomes of patients with localized and non-localized disease differed widely; the 5-year OS of 
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patients with localized disease was 83% as compared to only 29% for patients with non-localized 
disease.(Vang, et al 2000) This supports our observation of poor outcomes for patients with advanced 
stage disease and uterine involvement. 
In our study, 7/17 (41%) women with uterine DLBCL experienced SCNS and this was the major 
determinant of the poor outcomes seen in patients with reproductive organ involvement. Our 
findings are consistent with the series by Cao et al in which 4/6 patients with reproductive organ 
involvement experienced SCNS (3/4 had uterine involvement).(Cao, et al 2014) In the literature 
review by Mandato et al, at least two out of five patients with disease recurrence <6 months after 
treatment had SCNS.(Mandato, et al 2014) Thus, the risk of SCNS among women with uterine 
involvement by DLBCL appears to be substantial and clinically relevant, although the simultaneous 
presence of R-IPI high-risk disease is a confounder. However, uterine DLBCL was associated with SCNS 
after adjustment for other risk factors and the observed cumulative incidence for this group of 
patients was substantially higher than the 2-year cumulative SCNS risk of 12% reported for CNS-IPI 
high-risk disease.(Savage, et al 2014) 
None of the 10 women with ovarian DLBCL as the only site of internal reproductive organ involvement 
developed SCNS, and involvement of ovaries was not associated with outcomes in multivariate 
analyses. In two retrospective case series including 13 patients with ovarian lymphoma, mainly 
limited stage DLBCL, the outcomes were favourable and similarly, no SCNS cases were 
reported.(Senol, et al 2014, Vang, et al 2000)  In contrast, Yun et al reported SCNS in 5/22 women 
with ovarian DLBCL without baseline CNS involvement, but4/5 had additional high-risk features for 
SCNS including IPI≥3.(Yun, et al 2010) Thus, data on SCNS risk with ovarian DLBCL is conflicting. The 
explanation for increased risk of SCNS with specific extranodal sites is unclear. From an embryologic 
standpoint, intermediate mesoderm gives rise to the internal female genital tract as well as other 
high-risk sites including the testes, kidneys, and adrenal glands.(Sadler 2015)   
This study has limitations inherent to its retrospective design. No central pathology review was 
performed and information regarding cell of origin and the presence of adverse cytogenetic lesions 
(MYC and BCL2 or BCL6 translocations) was not available in the vast majority of patients. Double hit 
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DLBCL is associated with an increased risk of SCNS and may have been present in at least some of the 
patients in our study with poor-risk disease and uterine DLBCL.(Oki, et al 2014, Savage, et al 2016). 
Uterine involvement by DLBCL was based on imaging alone in some patients, and it is relevant to 
question the presence of DLBCL in these lesions. However, the frequency of biopsy verification of 
uterine involvement (11/17 patients) was high, considering many presented with advanced stage 
disease with other sites potentially more amenable to diagnostic biopsy. We speculate that unusual 
presentation of DLBCL at these sites and the need to rule out more common malignancies, 
particularly endometrial adenocarcinoma, may account for the high rate of histology documentation. 
In contrast to uterine DLBCL, we did not observe poorer outcomes in female patients with ovarian 
DLBCL as the only site of reproductive organ involvement. Physiologic FDG-uptake can occur in 
relation to the ovulatory phase of the menstrual cycle in premenopausal women.(Lerman, et al 2004) 
However, the median age of the 10 patients with ovarian DLBCL as the only reproductive organ 
involvement was 60 years and only 2/10 were below 50 years. Therefore, misinterpretation of 
physiological FDG-uptake in the ovaries is unlikely to explain reporting of ovarian DLBCL in most cases. 
In conclusion, women with uterine involvement by DLBCL appear to have poor outcomes, largely 
related to the high risk of SCNS. Staging of the CNS at diagnosis in those patients is reasonable, and 
CNS prophylaxis should be considered. However, additional studies are needed to confirm whether 
DLBCL originating from the female reproductive organs carries a significant risk of SCNS, particularly in 
the absence of other high-risk features. 
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Tables and Figures 
Table 1: Detailed baseline characteristics and treatment information of female DLBCL patients with 
or without reproductive organ involvement.  
 
 
Female DLBCL patients (n=678) 
No reproducitve 
organ involvement 
(n=651) 
Ovarian 
involvement  
(n=10) 
P* 
Uterine 
involvement 
(n=17) 
P§ 
Median age, years (range) 65 (17-91) 60 (33-84) <0.001 66 (44-82) <0.001 
Ann Arbor stage, n (%) 
 Stage I-II 
 
 Stage III-IV 
 
243 (37) 
408 (63) 
 
0 
10 (100) 
 
0.02 
 
3 (18) 
14 (82) 
 
0.13 
More than one extranodal site, n (%) 154 (24) 6 (60) 0.02 12(71) <0.001 
Median number of extranodal sites, n (interquartile range) 1 (0-1) 2 (1-3) <0.001 2 (1-4) <0.001 
Kidney/adrenal involvement, n (%) 24 (4) 3 (30) 0.006 0 1.0 
Elevated LDH, n (%)¥ 335 (52) 7 (70) 0.35 10 (59) 0.63 
ECOG performance score >1, n (%)¥ 103 (16) 2 (20) 0.66 5 (29) 0.17 
R-IPI risk group, n (%)¥ 
 Very good risk (score 0) 
 
 Good risk (score 1-2) 
 
 Poor risk (score 3-4-5) 
 
71 (11) 
307 (48) 
266 (41) 
 
0  
4 (40) 
6 (60) 
0.53 
 
0 (0) 
4 (24) 
13 (76) 
 
0.017 
 
CNS prophylaxis including intrathecal treatment, n (%) 
 Systemic CNS prophylaxis  
 
 Intrathecal 
 
 
62 (10) 
87 (13) 
 
3 (30) 
3 (30) 
 
0.066 
0.14 
 
2 (12) 
2 (12) 
 
0.67 
1.0 
Consolidative radiotherapy, n (%) 209 (32) 1 (10) 0.18 5 (29) 1.00 
*P-values reflect comparison of female DLBCL patients with ovarian involvement (without simultaneous uterine 
involvement) versus female patients without internal reproductive organ involvement. 
§P-values reflect comparison of female DLBCL patients with uterine involvement (+/- ovarian involvement) versus female 
patients without internal reproductive organ involvement. 
¥Missing information regarding LDH values (n=6) and ECOG performance (n=1), therefore exact R-IPI was unavailable in 
seven patients.  
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Table 2: Treatment outcome in female DLBCL patients with or without reproductive organ 
involvement.  
 No reproductive 
organ involvement 
(n=651) 
Ovarian 
involvement 
(n=10) 
P* Uterine 
involvement 
(n=17) 
P§ 
4-yr PFS, % (95% CI) 72 (68-76) 70 (33-89) 0.61 26 (8-50) <0.001 
4-yr OS, % (95% CI) 79 (75-82) 69 (30-89) 0.41 33 (12-56) <0.001 
4-yr cumulative CNS relapse rate 4 (2-6) 0 0.58 44 (24-71) <0.001 
*P-values reflect comparison of female DLBCL patients with ovarian involvement (without simultaneous uterine 
involvement) versus female patients without internal reproductive organ involvement. 
§P-values reflect comparison of female DLBCL patients with uterine involvement (+/- ovarian involvement) versus female 
patients without internal reproductive organ involvement. 
Table 3: Associations between baseline clinic-pathological features and outcome (PFS and OS) in 
univariate and multivariate Cox regression analyses. HR=hazard ratio  
 PFS OS 
 Univariate HR (95%CI, P) Multivariate HR (95%CI, P) Univariate HR (95%CI, P) Multivariate HR (95%CI, P) 
Age >60 years 1.97 (1.41-2.76, P<0.001) 1.60 (1.14-2.26, P=0.007) 2.85 (1.86-4.35, P<0.001) 2.38 ( 1.55-3.66, P<0.001) 
ECOG performance >1 2.35 (1.71-3.24, P<0.001) 1.61 (1.16-2.25, P=0.005) 2.74 (1.93-3.90, P<0.001) 1.84 (1.28-2.64, P=0.001) 
Elevated LDH 2.87 (2.10-3.93, P<0.001) 2.08 (1.50-2.89, P<0.001) 3.35 (2.32-4.85, P<0.001) 2.46 (1.67-3.63, P<0.001) 
Stage III/IV disease 3.29 (2.27-4.76, P<0.001) 2.11 (1.41-3.15, P<0.001) 3.16 (2.07-4.82, P<0.001) 1.79 (1.13-2.84, P=0.013) 
>1 extranodal site  2.00 (1.49-2.69, P<0.001) 1.14 (0.82-1.57, P=0.43) 2.13 (1.53-2.97, P<0.001) 1.15 (0.80-1.67, P=0.45) 
Uterine DLBCL 3.13 (1.74-5.63, P<0.001) 2.28 (1.23-4.22, P=0.009) 3.57 (1.93-6.60, P<0.001) 2.34 (1.21-4.52, P=0.012) 
Ovarian DLBCL 1.72 (0.71-4.18, P=0.23) 0.95 (0.38-2.38, P=0.91) 2.03 (0.83-4.94, P=0.12) 1.12 (0.44-2.87, P=0.81) 
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FIGURE LEGENDS 
Figure 1A-C: Progression-free survival (A) and overall survival (B) for female DLBCL patients with or 
without internal reproductive organ involvement. Cumulative incidence curves (C) for secondary CNS 
involvement for female patients with versus without uterine involvement by DLBCL based on Fine and 
Gray’s competing risk model. 
 
 
 
 
 
 
 
 
 
 
 
